晚期尿路上皮癌进展至一线及二线抗PD-1/PD-L1后的临床结局
该回顾性多中心研究分析了270例晚期尿路上皮癌患者在接受抗PD-1/PD-L1治疗进展后的结局,其中一线免疫治疗进展69例,后线进展201例。一线进展后接受后续系统治疗(SST)者中位OS为6.8个月(95%CI 5.0-8.6),未接受SST者为1.9个月(95%CI 0.9-3.0);后线进展后SST亦与OS改善独立相关(HR 0.22,95%CI 0.13-0.36,p<0.001)。
要点
- 一线免疫进展后未接受SST者中位OS仅1.9个月,需警惕早期死亡风险。
- 后线免疫进展后接受SST与OS改善独立相关(HR 0.22,p<0.001)。
- 高疾病负荷(≥3个转移部位、肝/骨同时转移)预示更差生存。
核心结论
- 免疫检查点抑制剂(ICI)进展后接受后续系统治疗(SST)与总生存(OS)改善独立相关。
- 一线ICI进展患者若未接受SST,中位OS仅1.9个月,存在早期死亡风险。
研究设计与样本
- 回顾性分析10家欧洲机构2013年3月至2017年9月间进展至一线或后线抗PD-1/PD-L1治疗的尿路上皮癌患者。
- 共纳入270例患者,其中一线ICI进展69例,后线ICI进展201例。
主要发现
- 一线ICI进展者中57%接受SST,后线ICI进展者中34%接受SST。
- 多因素分析显示SST对OS的影响:一线HR 0.22(95%CI 0.10-0.51,p<0.001),后线HR 0.22(95%CI 0.13-0.36,p<0.001)。
- 一线ICI进展组接受与未接受SST的中位OS分别为6.8个月(95%CI 5.0-8.6)和1.9个月(95%CI 0.9-3.0)。
- 一线ICI进展组中,高疾病负荷(≥3个转移部位:HR 2.49,p=0.03;肝/骨同时转移:HR 3.93,p=0.03)预测更差生存。
- 后线ICI进展组中,ICI应答(HR 0.37,p=0.03)、较长ICI暴露(HR 0.89,p=0.002)和骨转移(HR 2.42,p<0.001)预测生存。
临床怎么用
- 对ICI进展的尿路上皮癌患者,应考虑给予后续系统治疗以改善生存。
- 一线ICI进展患者需密切监测,尤其高疾病负荷者,警惕早期死亡。
局限性
- 回顾性研究设计。
- 缺乏某些参数,限制分析解读。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Immune checkpoint inhibitors (ICIs) are approved for first-line (cisplatin unfit, PD-L1+) and platinum-refractory urothelial carcinoma (UC). Still, most patients experience progressive disease (PD) as the best response. Although higher response rates to subsequent systemic treatment (SST) have been described, post-PD outcome data are scarce. OBJECTIVE: To examine the outcome of UC patients who received SST and no SST after progressing to ICIs. DESIGN, SETTING, AND PARTICIPANTS: A retrospective analysis of UC patients progressing to frontline or later-line anti-PD-1/PD-L1 therapy in 10 European institutions was conducted between March 2013 and September 2017. INTERVENTION: Post-PD management as per standard practice. OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS: Overall survival (OS) was analyzed with a Kaplan-Meier model. Cox regression was used for multivariate analysis (MV). Impact of SST on OS was examined with a time-varying covariate model. RESULTS AND LIMITATIONS: A total of 270 UC patients with PD to ICIs (69 frontline, 201 later line) were analyzed. Of the patients, 57% of frontline-ICI-PD and 34% of later-line-ICI-PD patients received SST, and SST had an impact on OS in MV (frontline: hazard ratio [HR] 0.22, 95% confidence interval [CI] 0.10-0.51, p < 0.001; later line: HR 0.22, 95% CI 0.13-0.36, p < 0.001). In the frontline-ICI-PD group, median OS with and without SST was 6.8 mo (95% CI 5.0-8.6) and 1.9 mo (95% CI 0.9-3.0), respectively. High disease burden (three or more metastatic sites: HR 2.49, p = 0.03; simultaneous liver/bone metastases: HR 3.93, p = 0.03) predicted worse survival. In later-line-ICI-PD group, response to ICIs (HR 0.37, p = 0.03), longer exposure to ICIs (HR 0.89, p = 0.002), and bone metastasis (HR 2.42, p < 0.001) predicted survival. The retrospective nature of this study and a lack of certain parameters limit the interpretation of our analysis. CONCLUSIONS: Patients progressing to frontline ICIs are at risk of early death, excluding them from experiencing potential benefit from chemotherapy PATIENT SUMMARY: Our analysis suggests that outcomes after failing immunotherapy are poor, particularly in UC patients who received no prior chemotherapy.
引用
- Gómez de Liaño Lista A, van Dijk N, de Velasco Oria de Rueda G, et al. Clinical outcome after progressing to frontline and second-line Anti-PD-1/PD-L1 in advanced urothelial cancer. Eur Urol. 2019. PMID: 31699525. doi:10.1016/j.eururo.2019.10.004
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。